Cargando…

The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status

OBJECTIVES: To investigate the added value of assessing transcripts for the long cAMP phosphodiesterase-4D (PDE4D) isoforms, PDE4D5 and PDE4D9, regarding the prognostic power of the ‘CAPRA & PDE4D7' combination risk model to predict longitudinal postsurgical biological outcomes in prostate...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Strijp, Dianne, de Witz, Christiane, Heitkötter, Birthe, Huss, Sebastian, Bögemann, Martin, Baillie, George S., Houslay, Miles D., Bangma, Chris, Semjonow, Axel, Hoffmann, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582815/ https://www.ncbi.nlm.nih.gov/pubmed/31275657 http://dx.doi.org/10.1155/2019/8107807

Ejemplares similares

The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes
por: van Strijp, Dianne, et al.
Publicado: (2018)

The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes
por: Gulliver, Chloe, et al.
Publicado: (2022)

Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies
por: Gulliver, Chloe, et al.
Publicado: (2023)

Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression
por: Böttcher, R, et al.
Publicado: (2015)

Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases
por: Böttcher, René, et al.
Publicado: (2016)

Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners
por: Houslay, Kirsty F., et al.
Publicado: (2017)

5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013)

Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST
por: Heitkötter, Birthe, et al.
Publicado: (2016)

Significance of the TMPRSS2:ERG gene fusion in prostate cancer
por: Wang, Zhu, et al.
Publicado: (2017)

Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region
por: Gulliver, Chloe, et al.
Publicado: (2023)

Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid
por: Heitkötter, Birthe, et al.
Publicado: (2018)

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status
por: Mwamukonda, Kuwong, et al.
Publicado: (2009)

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer
por: Rastogi, Anshu, et al.
Publicado: (2014)

TMPRSS2-ERG fusion promotes prostate cancer metastases in bone
por: Deplus, Rachel, et al.
Publicado: (2016)

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
por: Krumbholz, Manuela, et al.
Publicado: (2019)

Impact TMPRSS2–ERG Molecular Subtype on Prostate Cancer Recurrence
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2021)

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
por: Esgueva, Raquel, et al.
Publicado: (2010)

Retracted: Phosphorylation of PDE4A5 by MAPKAPK2 attenuates fibrin degradation via p75 signalling
por: Houslay, K F, et al.
Publicado: (2019)

Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression
por: Yin, Lihong, et al.
Publicado: (2011)

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
por: Salagierski, Maciej, et al.
Publicado: (2010)

TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells
por: Zhou, Feng, et al.
Publicado: (2019)

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
por: Giunchi, Francesca, et al.
Publicado: (2020)

Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)
por: Cameron, Ryan T., et al.
Publicado: (2013)

Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains
por: Bolger, Graeme B., et al.
Publicado: (2015)

TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers
por: Hägglöf, Christina, et al.
Publicado: (2014)

Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer
por: Hansen, Ailin Falkmo, et al.
Publicado: (2016)

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
por: Kohaar, Indu, et al.
Publicado: (2020)

Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway
por: Afshari, Afsoon, et al.
Publicado: (2021)

A TMPRSS2‐ERG gene signature predicts prognosis of patients with prostate adenocarcinoma
por: Zhou, Emily, et al.
Publicado: (2020)

TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence
por: Fang, Lei, et al.
Publicado: (2022)

Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
por: Li, Chengxun, et al.
Publicado: (2023)

PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate Cancer
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

Two paths for stabilization of ERG in prostate carcinogenesis: TMPRSS2-ERG fusions and speckle-type pox virus and zinc finger protein mutations
por: Pascal, Laura E, et al.
Publicado: (2016)

Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG
por: Roberts, Justin M., et al.
Publicado: (2017)

Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer
por: Urbinati, Giorgia, et al.
Publicado: (2015)

TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer
por: Krstanoski, Zoran, et al.
Publicado: (2016)

TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
por: Semaan, Louie, et al.
Publicado: (2019)

Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2023)

Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer
por: Xu, Zhenyu, et al.
Publicado: (2018)

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells
por: Henderson, D J P, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0mn7f1mh7hgmeacckrnn37phhn